title: Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
abstract: OBJECTIVE
  Deletions of 8p and gains of 8q belong to the most frequent cytogenetic alterations in prostate cancer. The target genes of these alterations and their biological significance are unknown.
  
  
  METHODS
  To determine the relationship between chromosome 8 changes, and prostate cancer phenotype and prognosis, a set of 1.954 fully annotated prostate cancers were analyzed in a tissue microarray format by fluorescence in situ hybridization.
  
  
  RESULTS
  Both 8p deletions and 8q gains increased in number during different stages of prostate cancer progression. 8p deletions/8q gains were found in 26.1%/4.8% of 1,239 pT(2) cancers, 38.5%/9.8% of 379 pT(3a) cancers, 43.5%/8.9% of 237 pT(3b) cancers, 40.7%/14.8% of 27 pT(4) cancers, 39.1%/34.8% of 23 nodal metastases, 51.9%/33.3% of 27 bone metastases, and 45.5%/59.9% of 22 hormone refractory cancers (P < 0.0001 each). Both 8p deletions and 8q gains were also significantly associated with high Gleason grade and with each other (P < 0.0001 each). In primary tumors, 8p deletions were seen in only 27.3% of 1,882 cancers without 8q gain but in 57.4% of 122 tumors with 8q gain (P < 0.0001). Among cancers treated with radical prostatectomy, 8p deletions (P = 0.003) and 8q gains (P = 0.02) were associated with biochemical tumor recurrence. However, multivariate analysis (including prostate-specific antigen, pT/pN stage, Gleason score, and surgical margin status) did not reveal any statistically independent effect of 8p or 8q alterations on biochemical tumor recurrence.
  
  
  CONCLUSIONS
  8p deletions and 8q gains are relatively rare in early stage prostate cancer but often develop during tumor progression. The prognostic effect does not seem to be strong enough to warrant clinical application.
authors.affiliation: Departments of Gynecology, Institute of Pathology, Martini-Clinic, Prostate Cancer Center, University Medical Center, Hamburg, Germany.
authors.forename: Alexander T
authors.initials: AT
authors.lastname: El Gammal
authors.forename: Michael
authors.initials: M
authors.lastname: Brüchmann
authors.forename: Jozef
authors.initials: J
authors.lastname: Zustin
authors.forename: Hendrik
authors.initials: H
authors.lastname: Isbarn
authors.forename: Olaf J C
authors.initials: OJ
authors.lastname: Hellwinkel
authors.forename: Jens
authors.initials: J
authors.lastname: Köllermann
authors.forename: Guido
authors.initials: G
authors.lastname: Sauter
authors.forename: Ronald
authors.initials: R
authors.lastname: Simon
authors.forename: Waldemar
authors.initials: W
authors.lastname: Wilczak
authors.forename: Jörg
authors.initials: J
authors.lastname: Schwarz
authors.forename: Carsten
authors.initials: C
authors.lastname: Bokemeyer
authors.forename: Tim H
authors.initials: TH
authors.lastname: Brümmendorf
authors.forename: Jakob R
authors.initials: JR
authors.lastname: Izbicki
authors.forename: Emre
authors.initials: E
authors.lastname: Yekebas
authors.forename: Margit
authors.initials: M
authors.lastname: Fisch
authors.forename: Hartwig
authors.initials: H
authors.lastname: Huland
authors.forename: Markus
authors.initials: M
authors.lastname: Graefen
authors.forename: Thorsten
authors.initials: T
authors.lastname: Schlomm
mesh_terms: D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D002898:Chromosomes, Human, Pair 8; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D011379:Prognosis; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000235:genetics*; D046888:Tissue Array Analysis
chemical_list: D017430:Prostate-Specific Antigen